The team

Cerapedics is a passionate, customer-focused, research-based team

The Cerapedics team is dedicated to enhancing the science of bone repair by staying at the leading edge of osteobiologic science and product development.

To find out more about the Cerapedics Board and Leadership Team, please see below.

The Board

Anthony Koblish

Antony Koblish

Anthony Koblish is a medical device entrepreneur with 25 years of experience who has served on the Cerapedics board of directors since 2013. He is currently co-founder, president and CEO of TELA Bio, a biosurgical reconstruction company. Prior to founding TELA Bio, Mr. Koblish was president and CEO of Orthovita, a publicly traded orthobiologics and biosurgery medical device company, where he helped grow the company’s valuation from $30 million to a $316 million sale to Stryker Corporation.

Glen Kashuba

Glen Kashuba

Glen Kashuba has over 30 years of executive management experience leading medical device companies. Prior to becoming CEO in 2013, Glen served as the Worldwide President of Spine & Bone Healing Technologies, Inc., a Biomet company, and concurrently served as Senior Vice President on Biomet’s Worldwide Operating Board, encompassing their Orthopedics, Spine, Trauma, Biologics, and Sports Medicine businesses. Previously, he has held a number of Divisional president roles at Johnson & Johnson where he served as Worldwide President for Cordis Endovascular and Neurovascular and as Worldwide President for Codman Neuro Sciences and U.S. President of DePuy Spine. Mr. Kashuba earned his B.S in Industrial Engineering from Rutgers University. He completed additional course work in corporate finance including a corporate valuation program at the Harvard Business School, and specialized study programs such as Bio-engineers in Surgery at Clemson University and Bio-mechanics Skeletal System at the New Jersey Institute Technology.

Kenneth Abramowitz

Kenneth Abramowitz

Kenneth Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager. He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine “All-America Research Team” during 15 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for 9 years since 1987.

Douglas Kohrs

Douglas Kohrs

Douglas Kohrs has 35 years of experience in the medical device industry as a founder, board member, and executive of many innovative companies and non-profit organizations. He is currently managing director of Responsive Arthroscopy, a company focused on value-based healthcare solutions for sports medicine. Prior to Responsive Arthroscopy, Mr. Kohrs founded Responsive Orthopedics, which was acquired by Medtronic in 2016. He also has served as president and CEO of both organizations. He currently serves on the board of directors of six entities and is the president of the Foundation for Essential Needs, a non-profit focused on eradicating hunger.

Valeska Schroeder

Valeska Schroeder

Valeska has been a Managing Director of KCK’s Medical Technologies Investment Group since 2016. KCK is a single-family fund investing in a range of industries in private equity, growth capital, and venture capital, including a focus in medical technology. Valeska is a board member for KCK portfolio companies, including Cerapedics, Aerin Medical and BioInspire and a board observer for Intuity Medical and Reflexion Medical. Before joining KCK, Valeska held roles in product development, program management, and marketing in medical device companies, including VitalConnect, Acclarent, and NDC. Valeska obtained a BS, MS, and PhD from University of California at Berkeley in Materials Science and Engineering.

Greg Garfield

Greg Garfield

Greg Garfield currently serves as Head of Medical Technology Investments for the KCK Group. Previously, Greg was the General Manager of Laryngology and Emerging Therapies for J&J’s Acclarent subsidiary, which J&J purchased for $800M. Prior to this role, Greg served as Acclarent’s Chief Operating Officer focusing on developing and commercializing products for use by ENT physicians to improve and enhance patients’ lives. Greg has many years of experience in the medical technology industry in a variety of roles.

Andrew Tofe

Andrew Tofe, PHD

Andrew Tofe, PhD has over forty years of experience in developing and commercializing diagnostic and therapeutic products for bone disease and bone repair. This research and work in bone includes over 50 publications and patents. Dr. Tofe founded and served as President and Chief Executive Officer of CeraMed Dental, where he developed and brought to market three different types of bone substitutes, OsteoGraf®/N in 1990, OsteoGraf®/LD in 1994, PepGen P-15™ in 1999, and PepGen P-15 Flow in 2001. Dr. Tofe served as President and Chief Executive Officer from the transition of CeraMed Dental into Cerapedics, Inc until 2006.

Tyrell Rivers

Tyrell Rivers

Tyrell J. Rivers, Ph.D., has served as a member of the board of directors of Cerapedics since June 2018. Dr. Rivers is also an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Corvidia Therapeutics and Viela Bio, Inc. and previously G1 Therapeutics, Inc. (GTHX) and PhaseBio Pharmaceuticals, Inc. (PHAS). He also serves as a board observer for several private companies.

Nael Kassar

Leadership

Glen Kashuba

Glen Kashuba

CEO

Glen Kashuba has over 30 years of executive management experience leading medical device companies. Prior to becoming CEO in 2013, Glen served as the Worldwide President of Spine & Bone Healing Technologies, Inc., a Biomet company, and concurrently served as Senior Vice President on Biomet’s Worldwide Operating Board, encompassing their Orthopedics, Spine, Trauma, Biologics, and Sports Medicine businesses. Previously, he has held a number of Divisional president roles at Johnson & Johnson where he served as Worldwide President for Cordis Endovascular and Neurovascular and as Worldwide President for Codman Neuro Sciences and U.S. President of DePuy Spine. Mr. Kashuba earned his B.S in Industrial Engineering from Rutgers University. He completed additional course work in corporate finance including a corporate valuation program at the Harvard Business School, and specialized study programs such as Bio-engineers in Surgery at Clemson University and Bio-mechanics Skeletal System at the New Jersey Institute Technology.

Jeffrey G. Marx, Ph.D.

Jeffrey G. Marx, Ph.D.

President & COO

Jeffrey Marx serves as President & Chief Operating Officer, overseeing regulatory, quality, manufacturing, and R&D efforts for the company. With some two decades of experience in executive management with medical device companies, he brings considerable expertise in research & development, commercialization, sales management, business development and strategic planning. His experience includes over 13 years with Orthovita, where he was VP Corporate Development. When Orthovita was acquired by Stryker Orthobiologics, Jeff led the team that integrated the two companies; he continued as VP Corporate Development at Stryker. He has earned a Ph.D. in Ceramic Engineering from Missouri University of Science and Technology, Rolla MO.

John Tattory

John Tattory

CFO

John Tattory has over 25 years of financial leadership experience primarily in the biotechnology and life sciences sectors. He has broad-based experience in directing U.S. and international financial operations, executing strategic transactions, managing investor relations, and raising capital through equity and debt financings. Prior to joining Cerapedics he served as Chief Financial Officer at Windtree Therapeutics, a publicly traded, biotechnology company focused on the development of novel therapeutics intended to address acute cardiovascular and pulmonary diseases. While at Windtree, John was responsible for raising over $350 million in capital through public and private equity offerings, debt facilities and licensing agreements. Prior to joining Windtree, John held financial management positions at Bristol-Myers Squibb and Ernst & Young LLP. John is a certified public accountant (currently inactive status) and holds a B.S. in Commerce degree from Rider University.

matt_thomas

Matt Thomas

CCO

Matt Thomas has over 25 years of experience leading medical device businesses.  He has broad experience in strategy, business development, marketing, sales & new product development.  Prior to joining Cerapedics in 2020, Matt was Vice President & General Manager for Medtronic’s Spinal Cord Stimulation & Early Interventions pain business.  Previously, Matt also led a turnaround of Medtronic’s Kyphon business, returning it to growth for the first time since the acquisition.  He joined Medtronic in 2002 and also had leadership roles in spine, diabetes, and deep brain stimulation.  Prior to Medtronic, he was a product manager with Sonic Innovations and founder of HyperX, a health care data services company.  He has an MBA from Carnegie Mellon University, a BS in economics from the University of Utah and studied at Johns Hopkins University.

Andrew W. Barnes

Andrew W. Barnes

Sr. VP of U.S. Sales

Andrew Barnes is an experienced leader within medical device sales, having held various leadership positions with leading companies in biologics, spine, orthopedic and maxillofacial medicine. Beginning his career with Synthes Trauma, Spine & Maxillofacial, Andy worked with such leading companies as Globus Medical, Stryker Orthobiologics/Orthovita, Medtronic and MacroPore Biosurgery before joining Cerapedics as Vice President of U.S. Sales.

Brice Johnson

Brice Johnson

VP of Human Resources

Brice Johnson is a senior Human Resources leader with over 20 years of progressive HR experience. He has successfully managed human capital & led HR teams in Fortune 150, mid-size, & entrepreneurial organizations across varied industries including medical device, pharmaceutical, CPG/food, healthcare, animal health, & higher education.  He has broad experience aligning business and HR strategy with talent ensuring that the required structure, capabilities, culture, and leadership are developed and in place to achieve business and growth objectives.  Prior to joining Cerapedics, Brice held HR leadership positions with several companies including LivaNova and Eli Lilly and Company. Brice earned his Bachelor of Chemical Engineering degree from Georgia Institute of Technology.